Regeneron Acquires 23andMe for $256 Million Amid Privacy Concerns
The Facts
- Regeneron Pharmaceuticals has agreed to purchase genetic testing company 23andMe for $256 million through a bankruptcy auction, marking a significant decline from 23andMe's peak valuation of $6 billion when it went public in 2021.The acquisition follows 23andMe's Chapter 11 bankruptcy filing in March 2025, which came after a major data breach in 2023 affecting nearly seven million customers and the subsequent resignation of CEO Anne Wojcicki.Under the agreement, Regeneron will acquire all of 23andMe's assets except Lemonaid Health, with the genetic testing firm continuing to operate as a wholly-owned subsidiary while maintaining its consumer genome services.
The Spin
Narrative A
The acquisition represents a strategic opportunity to advance genomics-driven drug discovery and improve public health outcomes. Regeneron's proven track record in managing genetic data and research capabilities makes it an ideal steward for 23andMe's valuable database of 15 million DNA profiles. The deal ensures continuity of services while maintaining robust privacy protections.
Narrative B
The sale raises serious concerns about the commercialization of sensitive genetic information and the potential for privacy violations. Without comprehensive federal privacy regulations, there are limited ways to hold companies accountable for their data management practices. The transaction highlights the risks of entrusting personal genetic information to private companies facing financial difficulties.
Metaculus Prediction
© 2026 Improve the News Foundation.
All rights reserved.
Version 7.18.3